CWBR — CohBar Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
CohBar Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Cohbar Appoints Joseph Sarret As Chief Executive Officer And Director
Brief: Cohbar Completes Enrollment In The Phase 1B Clinical Trial For Cb4211 Under Development For Nash And Obesity
Brief: Cohbar Inc - Announced Selection Of Cb5138-3 As Lead Candidate For Advancement Into Ind-Enabling Activities
Brief: CohBar Files For Stock Shelf Of Up To 7.03 Million Shares
Brief: Cohbar Inc Announces Preclinical Collaboration With NIAID To Evaluate Potential Of CB5064 Analogs For Treatment Of Covid-19 ARDS
Brief: CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome
Brief: CohBar Reports Q3 Loss Per Share Of $0.06
Brief: CohBar Says CohBar Antifibrotic Peptide In Combination With Nintedanib Shows Enhanced Effects In An Idiopathic Pulmonary Fibrosis Model
CohBar: Tumbles on discounted stock-and-warrant offering
Brief: Cohbar Announces Pricing Of $15 Million Public Offering Of Common Stock And Warrants
Brief: CohBar Reports Proposed Public Offering Of Common Stock And Warrants
Brief: CohBar Files For Mixed Shelf Of Up To $100 Mln – SEC Filing
Brief: Cohbar Announces First Subjects Dosed In Its Phase 1B Clinical Trial For Cb4211 Under Development For Nash And Obesity
Brief: CohBar Reports Q2 Loss Per Share Of $0.09
Brief: Cohbar Resumes Cb4211 Phase 1B Clinical Trial
Brief: Cohbar Added To Russell 2000® Index And Raises $4.4M In ATM Offering
Brief: CohBar Files For Equity Shelf Of Upto $20 Mln
Brief: CohBar Q1 Loss Per Share $0.10